Retatrutide, an investigational triple receptor agonist developed by Eli Lilly, is generating significant interest as a potential next-generation treatment for obesity and type 2 diabetes. Unlike existing approved therapies, it simultaneously targets GLP-1, GIP, and glucagon receptors, a mechanism that early clinical data suggest may produce substantial metabolic effects. However, as with any emerging medicine, understanding the pros and cons of retatrutide is essential before drawing conclusions. This article examines what the current Phase 2 evidence shows, outlines known side effects and safety considerations, and explains the drug's regulatory status in the UK.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational once-weekly injectable triple receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors to reduce appetite, enhance insulin secretion, and potentially increase energy expenditure. It has not yet received MHRA or EMA approval.

Retatrutide is an investigational injectable medication being developed by Eli Lilly as a potential treatment for obesity and type 2 diabetes. It belongs to a novel class of drugs known as triple receptor agonists, distinguishing it from earlier-generation weight-loss medications. Specifically, retatrutide simultaneously activates three incretin and metabolic hormone receptors:

• GLP-1 (glucagon-like peptide-1) receptor – which reduces appetite and slows gastric emptying

• GIP (glucose-dependent insulinotropic polypeptide) receptor – which enhances insulin secretion and may improve fat metabolism

• Glucagon receptor – which may increase energy expenditure and, based on early clinical and preclinical data, could promote hepatic fat metabolism

This triple-action mechanism sets retatrutide apart from existing approved therapies such as semaglutide (a GLP-1 agonist) or tirzepatide (a dual GLP-1/GIP agonist). By engaging all three pathways simultaneously, retatrutide is designed to produce a more pronounced effect on body weight and metabolic health than single or dual agonists, though direct head-to-head comparative trials have not yet been conducted.

The glucagon receptor component is particularly noteworthy. Whilst glucagon typically raises blood glucose, early Phase 2 trial data suggest that, when combined with GLP-1 receptor activation, its net effect may include increased calorie burning and a potential reduction in liver fat, without causing clinically significant rises in blood sugar. These are early signals from limited data and should not be regarded as established clinical effects pending larger trials.

Retatrutide is administered as a once-weekly subcutaneous injection, similar in delivery to other medicines in this class. It remains under clinical investigation and has not yet received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA). It should only be used within the context of authorised clinical trials.

Potential Benefits of Retatrutide

Phase 2 data reported approximately 24% mean body weight reduction over 48 weeks at the highest dose, alongside improvements in HbA1c, waist circumference, and lipid profiles, though Phase 3 confirmation is required before firm conclusions can be drawn.

Early-phase clinical trial data for retatrutide have generated considerable interest within the medical and scientific community, primarily due to the scale of weight loss observed in participants. In a Phase 2 randomised controlled trial published in the New England Journal of Medicine in 2023 (Jastreboff et al., NEJM 2023), adults with obesity (without type 2 diabetes) who received the highest dose of retatrutide (12 mg weekly) achieved a mean body weight reduction of approximately 24% over 48 weeks. It is important to note that this figure comes from a relatively small Phase 2 study, and results from larger Phase 3 trials are needed before firm conclusions can be drawn. Direct comparisons with semaglutide or tirzepatide should be interpreted with caution, as no head-to-head trials have been conducted.

Beyond weight reduction, the same trial reported several additional metabolic outcomes as secondary or exploratory endpoints:

• Improved glycaemic control – reductions in HbA1c levels were observed in participants with type 2 diabetes in a separate Phase 2 cohort

• Reduced waist circumference – suggesting a decrease in visceral (abdominal) fat, which is associated with cardiovascular risk

• Improvements in lipid profiles – including reductions in triglycerides

• Potential signal for benefit in metabolic-associated steatotic liver disease (MASLD) – based on the glucagon receptor's proposed role in hepatic fat metabolism; this remains an exploratory finding

These metabolic outcomes are promising but should be regarded as hypothesis-generating at this stage. For patients with obesity-related comorbidities — such as hypertension, dyslipidaemia, or fatty liver disease — these combined effects could represent a clinically meaningful advance if confirmed in Phase 3 data. NICE guidance on obesity and weight management recognises that sustained weight loss of 10% or more can significantly reduce the risk of type 2 diabetes, cardiovascular disease, and musculoskeletal problems.

Long-term cardiometabolic safety data and dedicated cardiovascular outcome trial results are not yet available for retatrutide. These data are important for a full understanding of the drug's benefit–risk profile and will be central to any future regulatory assessment. Conclusions about retatrutide's full benefit profile should therefore remain cautious at this stage.

Known Side Effects and Safety Concerns

The most common side effects are gastrointestinal (nausea, vomiting, diarrhoea), typically mild to moderate; key safety concerns include heart rate elevation, hypoglycaemia risk with certain diabetes medicines, pancreatitis, and a class-relevant thyroid C-cell tumour caution.

As with other medicines in the incretin-based drug class, retatrutide is associated with a range of side effects, the majority of which relate to the gastrointestinal system. In Phase 2 trial data, the most commonly reported adverse effects included:

• Nausea (reported in a significant proportion of participants, particularly during dose escalation)

• Vomiting

• Diarrhoea

• Constipation

• Decreased appetite (which, whilst contributing to weight loss, can occasionally be excessive)

These effects were generally described as mild to moderate in severity and tended to diminish over time as the body adjusted to the medication. Dose escalation protocols — where the dose is gradually increased over several weeks — are typically used to minimise gastrointestinal discomfort.

Patients experiencing severe or persistent vomiting or diarrhoea should be aware of the risk of dehydration and acute kidney injury (AKI). If you are unable to keep fluids down, you should seek prompt medical attention.

Of greater clinical significance are potential safety concerns that require further investigation in larger trials:

• Heart rate elevation – glucagon is known to have chronotropic effects, and increases in resting heart rate were observed in some trial participants; this warrants careful monitoring, particularly in individuals with pre-existing cardiac conditions

• Hypoglycaemia – whilst retatrutide alone has a low intrinsic risk of hypoglycaemia, people with type 2 diabetes who are also taking insulin or sulfonylureas face an increased risk; healthcare professionals should review concomitant diabetes medicines before and during treatment

• Delayed gastric emptying – as with other GLP-1-based therapies, retatrutide may slow gastric emptying, which could affect the absorption of some oral medicines; patients taking critical oral medications (such as thyroid hormones or anticoagulants) should discuss this with their healthcare professional

• Pancreatitis – patients with a history of pancreatitis should exercise caution; severe or persistent abdominal pain should be assessed promptly

• Thyroid C-cell tumours – observed in rodent studies with GLP-1 receptor agonists; a direct causal link in humans has not been established, but patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) should avoid this class of medicine

• Gallbladder disease – rapid weight loss can increase the risk of gallstones and gallbladder inflammation

• Diabetic retinopathy – rapid improvement in glycaemic control has been associated with worsening of diabetic retinopathy in people with pre-existing disease; this is a class-relevant caution that should be discussed with a healthcare professional

• Pregnancy and breastfeeding – retatrutide should not be used during pregnancy or breastfeeding. As safety data in pregnancy are not available, women of childbearing potential should use effective contraception during treatment. In line with practice for similar agents, a washout period before planned pregnancy should be discussed with a healthcare professional

Patients experiencing severe or persistent abdominal pain, signs of an allergic reaction, or significant changes in heart rate should seek prompt medical advice.

Reporting side effects: If you experience a suspected side effect from any medicine, including investigational treatments received within a clinical trial, you can report it via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. Healthcare professionals should also report suspected adverse reactions through this scheme.

Current Availability and Regulatory Status in the UK

Retatrutide is not approved for clinical use in the UK and has no MHRA or EMA marketing authorisation; it is only accessible through authorised Phase 3 clinical trials, with NHS availability subject to future regulatory and NICE assessment.

As of the time of writing, retatrutide is not approved for clinical use in the United Kingdom. It has not received a marketing authorisation from the MHRA, nor has it been granted approval by the EMA. The drug remains in active clinical development, with Phase 3 trials currently underway evaluating retatrutide's efficacy and safety across broader populations, including individuals with obesity, type 2 diabetes, and cardiovascular disease. Patients interested in the Phase 3 programme should check ClinicalTrials.gov or the EU Clinical Trials Register for current trial identifiers, eligibility criteria, and participating sites, as the programme name and trial details should be verified against these authoritative registers.

In the UK, the regulatory pathway for new medicines requires the MHRA to assess comprehensive evidence of safety, efficacy, and quality before granting a marketing authorisation. Following any potential approval, NICE would then evaluate the drug's cost-effectiveness to determine whether it should be recommended for use within the NHS. Given the costs typically associated with injectable weight-management therapies and existing NHS prescribing frameworks, access — if approved — may initially be limited to specific patient groups meeting defined clinical criteria, as has been the case with other agents in this class.

For patients currently seeking weight management support, the NHS offers a range of evidence-based options. NICE-recommended pharmacological treatments currently include:

• Orlistat – available on NHS prescription

• Semaglutide (Wegovy®) – approved by the MHRA for chronic weight management and subject to a phased NHS rollout, with eligibility criteria defined by NICE technology appraisal

• Tirzepatide (Zepbound®) – approved by the MHRA for chronic weight management; Mounjaro® (also tirzepatide) holds a separate MHRA authorisation for the treatment of type 2 diabetes

Patients should note that Mounjaro® and Zepbound® contain the same active ingredient (tirzepatide) but are authorised for different indications; prescribing should follow the relevant licensed indication and NICE guidance.

Patients interested in retatrutide may wish to explore participation in clinical trials. The NIHR 'Be Part of Research' portal (bepartofresearch.nihr.ac.uk) provides information on trials recruiting in the UK and can help identify whether any retatrutide studies are open to participants. Eligibility criteria apply to all trials.

Anyone considering weight management treatment should consult their GP or a specialist obesity service in the first instance. NHS specialist weight management services can provide access to multidisciplinary support, including dietary, behavioural, and pharmacological interventions. Self-prescribing or obtaining unregulated medicines online carries significant safety risks and is strongly discouraged.

Frequently Asked Questions